Capricor Therapeutics, Inc.
CAPR
$31.11
$0.210.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -7.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -7.92% |
| Cost of Revenue | 58.93% | 72.42% | 76.31% | 70.40% | 46.42% |
| Gross Profit | -575.53% | -113.27% | -158.37% | -205.38% | -259.43% |
| SG&A Expenses | 41.00% | 71.06% | 85.48% | 49.01% | 24.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.86% | 72.11% | 78.11% | 64.66% | 40.82% |
| Operating Income | -278.84% | -102.03% | -139.14% | -143.36% | -500.66% |
| Income Before Tax | -324.02% | -95.68% | -135.56% | -149.04% | -833.60% |
| Income Tax Expenses | 0.00% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -323.95% | -95.68% | -135.56% | -149.04% | -833.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -323.95% | -95.68% | -135.56% | -149.04% | -833.81% |
| EBIT | -278.84% | -102.03% | -139.14% | -143.36% | -500.66% |
| EBITDA | -291.41% | -103.89% | -142.41% | -147.40% | -651.82% |
| EPS Basic | -286.24% | -41.63% | -64.13% | -71.09% | -542.17% |
| Normalized Basic EPS | -292.68% | -41.57% | -64.10% | -70.08% | -534.19% |
| EPS Diluted | -286.24% | -41.63% | -64.13% | -71.09% | -542.17% |
| Normalized Diluted EPS | -292.68% | -41.57% | -64.10% | -70.08% | -534.19% |
| Average Basic Shares Outstanding | 9.75% | 38.16% | 43.55% | 45.55% | 45.15% |
| Average Diluted Shares Outstanding | 9.75% | 38.16% | 43.55% | 45.55% | 45.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |